GT200600282A - Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)-amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)-propoxi]-3-quinolincarbonitrilo y metodos para preparacion de las mismas. - Google Patents

Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)-amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)-propoxi]-3-quinolincarbonitrilo y metodos para preparacion de las mismas.

Info

Publication number
GT200600282A
GT200600282A GT200600282A GT200600282A GT200600282A GT 200600282 A GT200600282 A GT 200600282A GT 200600282 A GT200600282 A GT 200600282A GT 200600282 A GT200600282 A GT 200600282A GT 200600282 A GT200600282 A GT 200600282A
Authority
GT
Guatemala
Prior art keywords
metoxifenil
propoxi
metoxi
dicloro
amino
Prior art date
Application number
GT200600282A
Other languages
English (en)
Inventor
Marc Sadler Tesconi
Gregg Feigelson
Henry Strong
Hong Wen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600282(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600282A publication Critical patent/GT200600282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

ESTA INVENCIÓN ESTÁ DIRIGIDA A UN 4-[(2,4-DICLORO-5-METOXIFENIL)-AMINO]-6-METOXI-7-[3-(4-METIL-1-PIPERAZINIL)-PROPOXI]-3-QUINOLINCARBONITRILO MONOHIDRATO CRISTALINO QUE POSEE UN PATRÓN DE DIFRACCIÓN DE RAYOS X EN DONDE LOS ÁNGULOS 2-TETA (°) DE PICOS SIGNIFICATIVOS SE ENCUENTRAN A APROXIMADAMENTE: 9,19, 11,48, 14,32, 19,16, 19,45, 20,46, 21,29, 22,33, 23,96, 24,95, 25,29, 25,84, 26,55, 27,61, Y 29,51 Y UNA TEMPERATURA DE TRANSICIÓN DE APROXIMADAMENTE 109°C A APROXIMADAMENTE 115°C. T2006
GT200600282A 2005-07-01 2006-06-29 Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)-amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)-propoxi]-3-quinolincarbonitrilo y metodos para preparacion de las mismas. GT200600282A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
GT200600282A true GT200600282A (es) 2007-02-14

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600282A GT200600282A (es) 2005-07-01 2006-06-29 Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)-amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)-propoxi]-3-quinolincarbonitrilo y metodos para preparacion de las mismas.

Country Status (25)

Country Link
US (2) US7767678B2 (es)
EP (1) EP1902029B2 (es)
JP (1) JP2009500332A (es)
KR (1) KR20080028386A (es)
CN (1) CN101248047A (es)
AR (1) AR054505A1 (es)
AU (1) AU2006266045A1 (es)
BR (1) BRPI0613574A2 (es)
CA (1) CA2613053C (es)
CR (1) CR9596A (es)
DK (1) DK1902029T4 (es)
EC (1) ECSP078063A (es)
ES (1) ES2449197T5 (es)
GT (1) GT200600282A (es)
HK (1) HK1114614A1 (es)
IL (1) IL188483A0 (es)
MX (1) MX2008000384A (es)
NO (1) NO20080051L (es)
PA (1) PA8685101A1 (es)
PE (1) PE20070190A1 (es)
PL (1) PL1902029T5 (es)
PT (1) PT1902029E (es)
RU (1) RU2007148072A (es)
TW (1) TW200740797A (es)
WO (1) WO2007005462A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102470109A (zh) * 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
MXPA06001590A (es) * 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005047259A1 (en) * 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
BRPI0611977A2 (pt) 2005-06-24 2010-10-13 Wyeth Corp uso de um composto
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
CR9596A (es) 2008-03-06
US7767678B2 (en) 2010-08-03
DK1902029T4 (da) 2022-02-28
NO20080051L (no) 2008-01-29
TW200740797A (en) 2007-11-01
US20100324066A1 (en) 2010-12-23
US8445496B2 (en) 2013-05-21
WO2007005462A1 (en) 2007-01-11
ES2449197T3 (es) 2014-03-18
EP1902029A1 (en) 2008-03-26
CA2613053C (en) 2015-11-24
AR054505A1 (es) 2007-06-27
HK1114614A1 (en) 2008-11-07
CA2613053A1 (en) 2007-01-11
MX2008000384A (es) 2008-03-07
BRPI0613574A2 (pt) 2016-11-16
EP1902029B2 (en) 2022-02-16
ES2449197T5 (es) 2022-04-28
PT1902029E (pt) 2014-03-05
KR20080028386A (ko) 2008-03-31
DK1902029T3 (en) 2014-02-17
AU2006266045A1 (en) 2007-01-11
EP1902029B1 (en) 2014-01-08
PL1902029T5 (pl) 2022-08-29
US20070015767A1 (en) 2007-01-18
PA8685101A1 (es) 2007-01-17
PL1902029T3 (pl) 2014-08-29
IL188483A0 (en) 2008-04-13
PE20070190A1 (es) 2007-03-20
RU2007148072A (ru) 2009-08-10
ECSP078063A (es) 2008-01-23
JP2009500332A (ja) 2009-01-08
CN101248047A (zh) 2008-08-20

Similar Documents

Publication Publication Date Title
GT200600282A (es) Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)-amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)-propoxi]-3-quinolincarbonitrilo y metodos para preparacion de las mismas.
DK1928872T3 (da) Hidtil ukendte sulfonylpyrroler som inhibitorer af hdac
SV2008002542A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv)
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
ECSP078032A (es) Modificaciones cristalinas de la piraclostrobina
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
NO20081636L (no) FAP - inhibitorer
EA200801663A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1'-(1-МЕТИЛЭТИЛ)-4'-[(2-ФТОР-4-МЕТОКСИФЕНИЛ)МЕТИЛ]-5'-МЕТИЛ-1H-ПИРАЗОЛ-3'-O-β-D-ГЛЮКОПИРАНОЗИДА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
DK1877379T3 (da) Hydroxybenzamidderivater og anvendelse heraf som inhibitorer af hsp90
DK1725528T3 (da) Sulfonylpyrroler som hdac-inhibitorer
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
LTC1912640I2 (lt) HDAC inhibitoriaus panobinostato panaudojimas mielomos gydymui
DE602004008227D1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
CR9840A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urologicos
DK1954690T3 (da) Benzamidforbindelser, der er anvendelige som inhibitorer af histondeacetylase
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
BRPI0507998A (pt) uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
ES1064683Y (es) Aparato para la modificacion de la temperatura
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
AR065896A1 (es) Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina
NO20043842L (no) Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX